Advice
Following a full submission
anidulafungin (Ecalta) is not recommended for use within NHS Scotland for the treatment of invasive candidiasis in adult non-neutropenic patients.
Anidulafungin has been shown to be at least as effective as an alternative antifungal in a study of patients of whom the majority had candidaemia. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice90KB (PDF)
Medicine details
- Medicine name:
- anidulafungin (Ecalta)
- SMC ID:
- 465/08
- Indication:
- For the treatment of invasive candidiasis in adult non-neutropenic patients
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 June 2008